NBNeurocrine Biosciences NBIX · NASDAQ
$135.71 -0.91% (-$1.24)
- Market cap
- $13.9B
- Enterprise value
- $14.0B
- P/E
- 19.7x
- Forward P/E
- 20.6x
- PEG
- 0.7x
- P/S
- 4.1x
- P/FCF
- 16.0x
- EV/EBITDA
- 15.2x
- ROIC
- 13.2%
- Gross margin
- 98.0%
- Net margin
- 20.9%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- 0.1x
- Beta
- 0.40
- Free float
- 98.7%
About the company
Neurocrine Biosciences, Inc. is an American biotechnology company headquartered in San Francisco, California. The company focuses on the development of drugs for the treatment of neurological and endocrine disorders. Their main products include medications for the treatment of sleep disorders, movement disorders, and endocrine disorders such as diabetes. Neurocrine Biosciences specializes in research and development of new drug formulations targeting specific biological targets related to neurological and endocrine diseases. The company is known for its innovative drugs and technologies that help patients with these serious conditions. Shares of Neurocrine Biosciences, Inc. are publicly traded on the NASDAQ stock exchange.
Sector
Healthcare
Industry
Biotechnology
CEO
Kyle W. Gano
Employees
2,500
Headquarters
San Diego
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number